This site is currently implementing core features and is not ready for patient use yet.
This site is currently implementing core features and is not ready for patient use yet.
For informational purposes only — not medical advice
Get a free vaccination guide and nearby clinic recommendations — straight to your inbox.
How serious?
Risk of death
No
Vaccine available?
Time to symptoms
Countries affected
Active outbreaks
Very low risk for typical travelers. Associated with contact with infected livestock or mosquito bites during outbreaks in Sub-Saharan Africa and the Arabian Peninsula. Avoid contact with animal blood/tissues and use mosquito protection during reported outbreaks.
Viral zoonosis primarily affecting livestock (cattle, sheep, goats) in Africa and the Arabian Peninsula. Transmitted to humans by mosquito bites or contact with infected animal blood/tissues. Most cases mild, but ~8–10% develop severe complications including hemorrhagic fever, encephalitis, or retinitis.
Symptoms | Frequency | Severity | Onset |
|---|---|---|---|
| Fever | 90% | Moderate | Early |
| Headache | 75% | Mild | Early |
| Malaise | 65% | Mild | Early |
| Myalgia | 70% | Moderate | Early |
| Back pain | 50% | Moderate | Early |
| Chills | 40% | Mild | Early |
| Arthralgia | 35% | Mild | Peak |
| Hepatomegaly | 3% | Moderate | Peak |
| Jaundice | 2% | Severe | Peak |
| Loss of appetite | 50% | Mild | Peak |
| Nausea | 40% | Mild | Peak |
| Petechiae | 1.5% | Severe | Peak |
| Vomiting | 30% | Mild | Peak |
| Bleeding gums | 1% | Severe | Peak |
| Bloody stool | 0.8% | Severe | Peak |
| Bruising | 1% | Moderate | Peak |
| Dizziness | 30% | Mild | Peak |
| Hemorrhage | 1.5% | Critical | Peak |
| Blurred vision | 2% | Moderate | Late |
| Neck stiffness | 0.7% | Severe | Late |
| Severe headache | 0.8% | Severe | Late |
| Altered consciousness | 0.25% | Critical | Late |
| Confusion | 0.6% | Severe | Late |
| Eye pain | 1.5% | Moderate | Late |
| Photophobia | 1.5% | Mild | Late |
| Seizures | 0.3% | Critical | Late |
| Fatigue | 70% | Mild | Any phase |
Rift Valley fever (RVF) is an acute viral zoonosis caused by the Rift Valley fever virus (RVFV), a member of the genus Phlebovirus in the family Phenuiviridae (order Bunyavirales). First identified in 1931 during an investigation of an epizootic among sheep in the Rift Valley of Kenya, the virus has since caused major outbreaks across Africa and the Arabian Peninsula.
RVFV is primarily transmitted by mosquitoes, particularly Aedes and Culex species. The virus is unique among arboviruses in its capacity for transovarial transmission in Aedes mosquitoes, allowing the virus to survive prolonged dry periods in mosquito eggs that hatch when flooding occurs. Humans also acquire infection through direct contact with blood, body fluids, or tissues of infected animals, particularly during slaughter, veterinary procedures, or handling of aborted animal fetuses.
The majority of human infections are self-limiting febrile illnesses. However, approximately 8-10% of patients develop severe complications including ocular disease, meningoencephalitis, or hemorrhagic fever. The overall case fatality rate is less than 1%, but the hemorrhagic form carries a CFR of approximately 50%.
RVF is of major One Health significance because it causes devastating epizootics in livestock (cattle, sheep, goats, camels), with abortion rates approaching 100% in pregnant ewes and high mortality in young animals. Outbreaks result in enormous agricultural and economic losses. The disease is listed as a WHO-notifiable condition and is a priority pathogen on the WHO R&D Blueprint for emerging diseases.
Clinical Overview
Rift Valley fever presents unique challenges due to its dual impact on human health and livestock economies, its explosive outbreak potential linked to climatic events, and the absence of approved human vaccines or specific treatments.
Key Clinical Facts:
Causative agent: Rift Valley fever virus (Phlebovirus, family Phenuiviridae)
Transmission: Mosquito bite (Aedes, Culex spp.); direct contact with infected animal tissues/fluids; rare aerosol transmission in laboratory settings
Reservoir: Livestock (cattle, sheep, goats, camels); mosquito eggs (transovarial)
Incubation period: 2-6 days
Clinical spectrum: ~50% asymptomatic, ~48% mild febrile illness, ~8-10% severe (ocular, encephalitic, hemorrhagic)
Case fatality rate: <1% overall; hemorrhagic form ~50%
Treatment: No approved antiviral; supportive care only
Vaccine: No licensed human vaccine; veterinary vaccines available
Global Significance: RVF outbreaks cause simultaneous human disease and massive livestock losses. The 2006-2007 outbreak in Kenya, Somalia, and Tanzania resulted in over 1,000 human cases with 394 deaths and an estimated $60 million in livestock losses. The virus has repeatedly demonstrated capacity to spread to new geographic areas, as evidenced by its emergence in the Arabian Peninsula in 2000.
Outbreak Dynamics: RVF epidemics are characteristically linked to periods of heavy, sustained rainfall and flooding, which trigger mass hatching of Aedes mosquito eggs carrying transovarially-transmitted virus. El Nino/Southern Oscillation (ENSO) events are strongly associated with East African RVF outbreaks.
Emergency Warning Signs
While most RVF cases are mild, severe forms can be rapidly fatal. Seek immediate medical attention if any of the following develop during or after a febrile illness in a person with RVF exposure risk:
Hemorrhagic Fever Warning Signs (Highest Urgency):
Vomiting blood (hematemesis) or passing black/bloody stools (melena)
Jaundice (yellowing of skin and eyes) — indicates severe hepatic necrosis
Bleeding from gums, nose, injection sites, or skin (petechiae, purpura, ecchymoses)
Rapid clinical deterioration after initial improvement of febrile illness
Abdominal pain with hepatomegaly and tenderness (liver involvement)
Oliguria or anuria — indicates renal failure
Neurological Warning Signs:
Confusion, disorientation, or altered consciousness — may indicate meningoencephalitis
Seizures — new onset, especially in febrile context
Severe headache with neck stiffness
Hallucinations or behavioral changes
Focal neurological deficits (weakness, speech difficulty)
Ocular Warning Signs:
Sudden decrease in vision — especially if bilateral
Visual field defects or scotomas
Onset typically 1-3 weeks after febrile episode
Clinical Context: These warning signs should raise particular concern in persons who have:
Been in RVF-endemic areas during or after heavy rainfall/flooding
Had contact with sick or dead livestock, aborted animal fetuses, or animal blood
Worked as butchers, veterinarians, or herders in affected areas
Developed fever within 2-6 days of potential exposure
Key Message: The hemorrhagic form of RVF has a ~50% fatality rate. Early recognition and intensive supportive care are the only available interventions.
Most common signs and symptoms
Symptom Presentation
Rift Valley fever has a broad clinical spectrum ranging from asymptomatic infection to fatal hemorrhagic disease.
Mild/Uncomplicated RVF (90-95% of symptomatic cases):
Incubation period of 2-6 days followed by abrupt onset
Fever (38.5-40°C), often biphasic (initial fever resolves, then recurs)
Severe headache, typically frontal and retro-orbital
Myalgia and arthralgia (often severe, affecting the back and limbs)
Malaise and fatigue
Anorexia, nausea, and occasionally vomiting
Facial flushing, conjunctival injection
Duration: typically 4-7 days with spontaneous resolution
Severe Disease Forms (8-10% of cases):
Ocular Disease (0.5-2% of all infections):
Meningoencephalitis (< 1% of all infections):
Hemorrhagic Fever (< 1% of all infections):
Knowing the symptoms is the first step to a quick response.
Disease Course and Progression
The natural history of RVF follows a characteristic pattern with potential for late-onset complications weeks after the initial febrile illness.
Exposure (Day 0):
Mosquito bite (primarily Aedes or Culex species) during periods of heavy rainfall/flooding
OR direct contact with blood, tissues, or fluids of infected livestock (slaughter, birthing, veterinary procedures, handling aborted material)
OR rare: inhalation of aerosols in laboratory settings
Incubation Period (Days 1-6, typically 2-6):
Virus replicates at the inoculation site and in regional lymph nodes
Viremia develops, with potential dissemination to liver, spleen, and other organs
The patient is asymptomatic during this period
Acute Febrile Phase (Days 2-10):
Abrupt onset of fever, often biphasic (initial fever may resolve for 1-2 days before recurring)
Severe headache, retro-orbital pain, myalgia, arthralgia
Facial flushing, conjunctival injection
Nausea, anorexia
Duration: typically 4-7 days with gradual improvement
Most patients (~90%) recover fully during this phase
Severe Disease Branching (Variable Timing):
Hemorrhagic Form (Days 2-4 after fever onset):
Typically the earliest severe complication
Jaundice, hepatomegaly, and abdominal pain signal liver involvement
Progressive bleeding manifestations over 24-72 hours
DIC develops with laboratory coagulopathy
Multi-organ failure may follow
Death usually occurs 3-6 days after hemorrhagic onset
Ocular Form (Weeks 1-3 after fever onset):
Delayed onset, often after apparent recovery from febrile illness
Gradual visual symptoms: blurring, decreased acuity, scotomas
Retinal lesions may progress over days to weeks
Some lesions resolve; macular lesions often cause permanent damage
Encephalitic Form (Weeks 1-4 after fever onset):
Most delayed severe complication
Progressive confusion, behavioral changes, headache
May progress to stupor, coma, focal deficits, seizures
Prolonged course: recovery over weeks to months
Convalescence:
Uncomplicated cases: full recovery within 1-2 weeks
Severe cases: prolonged convalescence over weeks to months
Late-onset complications (ocular, encephalitic) may emerge after apparent recovery
How this disease is identified
Diagnosis
RVF diagnosis requires integration of clinical presentation, epidemiological context (geographic, seasonal, occupational), and laboratory confirmation. Diagnosis is particularly challenging because early symptoms are nonspecific.
Clinical Suspicion: RVF should be suspected in febrile patients with:
Recent travel to or residence in an RVF-endemic area, especially during heavy rainfall/flooding
Occupational exposure to livestock (butchers, herders, veterinarians, abattoir workers)
Concurrent livestock abortion storms or animal deaths in the area
Hemorrhagic manifestations, hepatitis, or retinitis during a febrile illness
Laboratory Diagnostic Methods:
RT-PCR (Reverse Transcription Polymerase Chain Reaction):
IgM ELISA (Enzyme-Linked Immunosorbent Assay):
IgG ELISA:
Virus Isolation:
Immunohistochemistry:
Differential Diagnosis: The differential is broad and includes: malaria, dengue, Crimean-Congo hemorrhagic fever, Ebola/Marburg, yellow fever, leptospirosis, typhoid fever, viral hepatitis, and bacterial meningitis.
Laboratory Findings:
Elevated liver transaminases (often markedly: AST/ALT >1000 U/L in severe cases)
Thrombocytopenia
Leukopenia early, then leukocytosis
Prolonged PT/PTT and decreased fibrinogen in DIC
Elevated creatinine in cases with renal involvement
Available treatment methods
Treatment and Management
There is no approved specific antiviral therapy for Rift Valley fever. Management is entirely supportive and varies by disease severity.
Mild Disease (majority of cases):
Rest and adequate oral hydration
Antipyretics (paracetamol/acetaminophen) for fever and pain
Avoidance of aspirin and NSAIDs (risk of bleeding complications)
Monitoring for warning signs of progression to severe disease
Most patients recover fully within 1-2 weeks
Severe Disease — Hemorrhagic Form:
ICU-level care is required
Aggressive fluid resuscitation with crystalloids and colloids for shock
Blood product transfusion: Packed red blood cells, fresh frozen plasma, platelets, and cryoprecipitate for DIC management
Vitamin K if coagulopathy is present
Monitoring: Continuous hemodynamic monitoring, serial laboratory assessments (CBC, coagulation, liver/renal function)
Renal support: Hemodialysis or continuous renal replacement therapy (CRRT) if acute kidney injury develops
Liver failure management: N-acetylcysteine may have a role; liver transplantation is not practical in outbreak settings
Severe Disease — Meningoencephalitis:
Supportive neurological care
Seizure management with benzodiazepines and anticonvulsants
Raised intracranial pressure management
Prolonged rehabilitation for neurological sequelae
Severe Disease — Ocular:
Ophthalmological evaluation and monitoring
Corticosteroids have been used but efficacy is unproven
No antiviral therapy demonstrated to improve ocular outcomes
Laser photocoagulation for retinal neovascularization if indicated
Investigational Therapies:
Ribavirin: Has shown in vitro activity against RVFV and some animal model efficacy. Used compassionately in some outbreaks but no controlled human trials demonstrate benefit. WHO does not currently recommend routine use.
Favipiravir (T-705): Promising preclinical data; under investigation
Monoclonal antibodies: In preclinical development
Interferon-alpha: Early animal studies show some benefit if given pre-exposure
Most cases are effectively treated with early diagnosis.
How to protect yourself
Prevention Strategies
There is no licensed human vaccine for RVF. Prevention relies on mosquito avoidance, safe animal handling practices, and veterinary vaccination programs to reduce the livestock reservoir.
Personal Protective Measures — Mosquito Avoidance:
Use EPA-registered insect repellents (DEET 20-30%, picaridin, IR3535)
Wear long-sleeved clothing and long pants, especially during daytime (Aedes bite during the day)
Use permethrin-treated clothing and gear
Sleep under insecticide-treated bed nets
Stay in screened or air-conditioned accommodations
Occupational Safety — Animal Contact:
Wear gloves, masks, and eye protection when handling livestock, especially during birthing, slaughter, and veterinary procedures
Avoid contact with aborted animal material (fetuses, placenta, amniotic fluid) — these contain very high viral loads
Do not consume raw or unpasteurized milk or undercooked meat from potentially infected animals
Practice thorough hand hygiene with soap and water after any animal contact
Report sick or dying livestock and animal abortion storms to veterinary authorities immediately
Veterinary and Community Measures:
Livestock vaccination: Several veterinary vaccines are available (live-attenuated MP-12, Clone 13; inactivated Smithburn). Vaccination of livestock before the rainy season can prevent epizootics and secondary human cases.
Movement restrictions: Quarantine of livestock from affected areas during outbreaks
Vector control: Larviciding of mosquito breeding sites (flooded areas, dambos), indoor residual spraying
Early warning systems: Satellite-based monitoring of rainfall, vegetation indices, and ENSO events can predict RVF outbreaks 2-4 months in advance (e.g., NASA/USGS RVFV forecasting models)
Human Vaccine Development:
MP-12 vaccine: Live-attenuated, highly immunogenic, single-dose. Under regulatory review in the US (conditionally licensed for veterinary use). Concerns about safety in immunocompromised and pregnant individuals.
formalin-inactivated vaccine (TSI-GSD-200): Previously used under IND for laboratory workers. Requires multiple doses and boosters. Limited availability.
ChAdOx1 RVF and DNA vaccines: In early clinical trials
No human vaccine is expected to be widely available before 2028
Preparation is the best protection.
Travel Advice
RVF poses a risk primarily to travelers visiting affected areas during outbreaks or those with occupational animal exposure. Risk for typical tourists is generally low.
Endemic and At-Risk Regions:
East Africa: Kenya, Tanzania, Somalia, Sudan, South Sudan — highest historical burden
Southern Africa: South Africa, Mozambique, Zimbabwe, Madagascar
West Africa: Mauritania, Senegal, Gambia, Nigeria
North Africa: Egypt (major epidemic in 1977-1978 with ~200,000 human cases)
Arabian Peninsula: Saudi Arabia, Yemen (emerged in 2000)
Potential expansion: Climate models suggest RVF could spread to currently unaffected regions of Asia and southern Europe
Outbreak Triggers: RVF outbreaks are strongly associated with:
Heavy, sustained rainfall and flooding (linked to ENSO/El Nino events)
Formation of large temporary water bodies in semi-arid areas
Rainy seasons following prolonged droughts
Pre-Travel Recommendations:
During Travel:
Apply insect repellent consistently during daytime and evening hours
Avoid handling livestock, especially during birthing or slaughter
Do not consume raw milk or undercooked meat in affected areas
Avoid contact with sick or dead animals
During active outbreaks, minimize time near flooded areas with abundant mosquitoes
Post-Travel:
Seek medical attention if fever develops within 2-14 days of returning from an endemic area
Inform clinicians of travel history and any animal exposure
Report any visual symptoms developing in the weeks following a febrile illness during travel (delayed ocular manifestation)
Statistics and geographic data
Epidemiology
Rift Valley fever is an emerging zoonotic disease with a growing geographic range and significant epidemic potential linked to climate variability.
Geographic Distribution:
Africa: Documented in over 30 countries across sub-Saharan and North Africa
Arabian Peninsula: Saudi Arabia and Yemen (first emergence outside Africa in 2000)
Indian Ocean Islands: Madagascar, Mayotte, Comoros
Potential range expansion: Mathematical models predict risk of establishment in southern Europe, the Middle East, and parts of Asia where competent vectors and susceptible livestock are present
Major Historical Outbreaks:
Egypt 1977-1978: An estimated 200,000 human cases and 594 deaths following Aswan Dam construction and irrigation changes
East Africa 1997-1998: Associated with strong El Nino; 89,000 estimated cases in Kenya and Somalia
Saudi Arabia/Yemen 2000: First outbreak outside Africa; 886 cases, 124 deaths
Kenya/Tanzania/Somalia 2006-2007: 1,062 cases, 394 deaths (WHO); devastating livestock losses
South Africa 2010-2011: 302 cases, 25 deaths
Niger/Mauritania 2016: 64 human cases
Kenya/Somalia 2018: Resurgent activity with cases reported during El Nino conditions
Transmission Ecology:
Mosquito-borne: Primary transmission via Aedes (transovarially infected) and secondary amplification by Culex, Anopheles, and other genera
Transovarial transmission: RVFV is maintained in Aedes mosquito eggs during inter-epidemic periods (dry years). Eggs survive in soil for years and hatch when flooded.
Zoonotic: Livestock (sheep, cattle, goats, camels) serve as amplifying hosts with high viremia
Direct contact: Significant route for occupational infections; aerosol exposure in laboratory settings
Burden Estimation: True burden is difficult to quantify due to:
Mild cases are indistinguishable from other febrile illnesses (malaria, dengue)
Limited surveillance infrastructure in most endemic countries
Outbreaks occur in remote pastoral areas with poor healthcare access
Estimated tens of thousands of cases during major epidemics; inter-epidemic cases are underdetected
Seasonality and Climate Linkage:
Outbreaks are strongly seasonal, linked to rainfall and flooding patterns
Inter-epidemic periods can last 5-20 years in any given location
ENSO prediction models can forecast outbreaks 2-4 months in advance with reasonable accuracy
Who is most at risk
Risk Factors
Risk factors for RVF operate at the population level (outbreak occurrence) and individual level (exposure and disease severity).
Population-Level Risk Factors (Outbreak Occurrence):
Heavy rainfall and flooding: The single most important predictor. Triggers mass hatching of transovarially-infected Aedes mosquito eggs.
El Nino/Southern Oscillation (ENSO) events: Strongly correlated with East African RVF outbreaks
Presence of competent vectors: Aedes and Culex mosquito species
High livestock density: Large numbers of susceptible (unvaccinated) domestic animals amplify the virus
Proximity of human habitation to livestock: Common in pastoral and agro-pastoral communities
Individual Risk Factors for Infection:
Occupational exposure (highest risk):
Direct animal contact: Handling animal blood, tissues, or aborted material without PPE. This route may result in higher viral inoculum and potentially more severe disease.
Mosquito exposure: Residing in or visiting areas with active RVF transmission, especially near flooded zones
Consumption of raw milk from infected animals (virus present in milk)
Residence in rural areas with limited vector control infrastructure
Risk Factors for Severe Disease:
Protective Factors:
Previous RVF infection appears to confer durable immunity
Consistent use of PPE during animal handling
Livestock vaccination programs that reduce epizootic amplification
Effective mosquito bite prevention measures
Potential complications
Complications
Although most RVF infections are mild, severe complications occur in 8-10% of cases and can be life-threatening or result in permanent disability.
Hemorrhagic Complications (Most Lethal):
Fulminant hepatic necrosis: The hallmark of severe RVF. Massive hepatocyte destruction leads to coagulopathy, encephalopathy, and death. Liver transaminases may exceed 10,000 U/L. The liver shows characteristic widespread, midzone hepatocellular necrosis with eosinophilic (Councilman-like) bodies.
Disseminated intravascular coagulation (DIC): Consumption coagulopathy with simultaneous thrombosis and hemorrhage
Gastrointestinal hemorrhage: Hematemesis and melena are common in hemorrhagic cases
Multi-organ failure: Hepatorenal syndrome, respiratory failure, and cardiovascular collapse
Case fatality rate: ~50% for the hemorrhagic form
Ocular Complications:
Retinal vasculitis: Inflammation and occlusion of retinal vessels, leading to ischemia and hemorrhage
Macular edema and retinal detachment: May occur acutely or as late complications
Permanent vision loss: Occurs in 1-10% of patients who develop ocular disease; up to 50% of those with macular involvement
Optic disc edema and vitritis: Less common but may contribute to visual impairment
Ocular complications typically manifest 1-3 weeks after the acute illness, often after apparent recovery
Neurological Complications:
Meningoencephalitis: Manifesting 1-4 weeks post-acute illness with confusion, seizures, focal deficits, coma
Long-term neurological sequelae: Cognitive impairment, personality changes, motor deficits reported in survivors
CFR for encephalitic form: 5-10%
Other Complications:
Chronic liver disease: May develop in survivors of severe hepatic involvement
Post-infectious fatigue: Prolonged recovery period
Psychological impact: Particularly in pastoral communities where simultaneous loss of livelihoods (livestock deaths) and human illness creates severe psychosocial stress
Secondary bacterial infections: In severely ill, hospitalized patients
Combined Manifestations: Some patients develop overlapping severe forms (e.g., hemorrhagic disease with encephalitis), which carry the worst prognosis. These combined presentations are associated with the highest mortality rates, approaching 70-80%.
Expected outcomes and recovery
Prognosis and Outcomes
The prognosis for RVF varies substantially depending on the clinical form.
Mild/Uncomplicated RVF:
Excellent prognosis with full recovery expected
Self-limiting illness resolving in 4-7 days
Overall CFR <1% for all RVF infections combined
Residual fatigue and myalgia may persist for 1-2 weeks
Convalescent immunity appears to be long-lasting
Ocular Disease:
Onset 1-3 weeks post-acute illness
1-10% of affected patients develop permanent vision loss
Up to 50% with macular involvement have significant permanent visual impairment
Peripheral retinal lesions generally have better visual outcomes
Risk of late complications (retinal detachment, neovascularization) persists for months
Meningoencephalitis:
CFR approximately 5-10%
Onset typically 1-4 weeks after acute illness
Recovery is slow (weeks to months)
Residual neurological deficits in a significant proportion of survivors: cognitive impairment, motor deficits, personality changes
Some patients may require long-term rehabilitation
Hemorrhagic Fever:
Most severe form with CFR of approximately 50%
Death typically occurs 3-6 days after onset of hemorrhagic symptoms
Severe hepatic necrosis is the primary cause of death
DIC and multi-organ failure contribute to mortality
Survivors may develop chronic liver disease
Predictors of Severe Disease:
High viral load in early illness
Elevated liver transaminases (AST, ALT) early in course
Thrombocytopenia and coagulopathy
Immunosuppression
Direct animal tissue exposure (may indicate higher inoculum)
Long-Term Outcomes:
Most patients (>90%) who survive the acute phase make a full recovery
Combined severe manifestations (e.g., hemorrhagic + encephalitic) carry the worst prognosis
Post-infectious fatigue syndrome is reported but poorly characterized
Immunity following natural infection appears durable
The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.
Full terms of useKnow which vaccine you need? Great. Not sure? Just tell us your destination — we will figure it out and match you with a clinic. Free, no obligation.